Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our App on Google Play! dexwirenews.com/APP
2) Text Message Notifications: dexwirenews.com/SMS
3) Telegram: t.me/DEXWireNews
4) Follow Us on our Social Networks
1) Download our App on Google Play! dexwirenews.com/APP
2) Text Message Notifications: dexwirenews.com/SMS
3) Telegram: t.me/DEXWireNews
4) Follow Us on our Social Networks